Cortisol And Autoimmune Disease Research

---

Table of Contents

• What Is the Cortisol-Autoimmune Connection?
• How the HPA Axis Shapes Immune Tolerance
• Are Cortisol Levels High or Low in Autoimmune Disease?
• Cortisol Research in Lupus, Hashimoto's, and Rheumatoid Arthritis
• How Researchers Measure Cortisol in Autoimmune Studies
• Chronic Stress, Cortisol Dysregulation, and Autoimmune Risk
• Does Glucocorticoid Therapy Change Long-Term HPA Function?
• Is Cortisol Protective or Harmful in Autoimmune Inflammation?
• Frequently Asked Questions
• Key Takeaways

---

Introduction

If you have an autoimmune disease — or you're trying to understand why your immune system turned against you — there is a very good chance you have come across the word cortisol. Maybe a doctor mentioned it. Maybe you read about it in the context of stress. Maybe you've wondered whether years of relentless pressure at work, a traumatic experience, or chronic anxiety could have something to do with your diagnosis.

You are not imagining that connection. The science linking cortisol and autoimmune disease research has grown substantially over the past decade, and what is emerging is a nuanced, sometimes paradoxical picture that deserves a careful look.

Cortisol is not simply the "bad stress hormone." It is a powerful immunomodulator. Its relationship with autoimmune diseases like lupus, Hashimoto's thyroiditis, and rheumatoid arthritis is complicated by timing, duration, individual biology, and the feedback loops of the hypothalamic-pituitary-adrenal (HPA) axis. A 2025 review summarized the current state of evidence bluntly: chronic stress-related HPA-axis dysregulation, elevated cortisol, and pro-inflammatory signaling are linked to a meaningfully higher risk of autoimmune disease onset and progression.

This post breaks down that evidence — the studies, the statistics, the mechanisms, and the questions that researchers are still working to answer.

---

---

What Is the Cortisol-Autoimmune Connection?

Cortisol is a glucocorticoid hormone produced by the adrenal cortex in response to signals from the brain. Under normal conditions, it plays an essential role in energy metabolism, blood pressure regulation, and — critically — immune modulation. In the short term, cortisol suppresses inflammation. It inhibits pro-inflammatory cytokines, reduces the activity of immune cells like T-lymphocytes and macrophages, and helps bring an immune response back under control once a threat has passed.

That anti-inflammatory function is precisely why synthetic glucocorticoids (like prednisone or dexamethasone) are used to treat autoimmune flares. The logic is straightforward: if your immune system is attacking your own tissue, something that suppresses immune activity should help.

But the picture from cortisol autoimmunity research is far more complicated than that.

When cortisol is chronically elevated — not because of a single stressor, but because of ongoing psychological or physiological stress — the immune system does not simply stay suppressed. Instead, immune cells begin to develop glucocorticoid resistance. Receptors that normally respond to cortisol become desensitized. The result is not a dampened immune response. It is an immune system that has lost a major brake, one that is now dysregulated rather than uniformly underactive or overactive.

This desensitization process is at the center of modern stress autoimmune research, and it helps explain why chronic stress appears to be a genuine risk factor for autoimmune onset — not just a trigger for flares in people who already have disease.

Additionally, cortisol interacts with the gut microbiome, the blood-brain barrier, reproductive hormones (which partly explains the female predominance in most autoimmune conditions), and epigenetic mechanisms that can alter immune gene expression over time. The cortisol-autoimmune connection is not one pathway. It is a network.

---

How the HPA Axis Shapes Immune Tolerance

To understand how cortisol drives or reflects autoimmune risk, you have to understand the hypothalamic-pituitary-adrenal axis. The HPA autoimmune disease relationship runs directly through this circuit.

Here is how the axis works under normal conditions:

1. The hypothalamus detects a stressor (physical, psychological, or immune-based) and releases corticotropin-releasing hormone (CRH).
2. CRH travels to the pituitary gland, which releases adrenocorticotropic hormone (ACTH).
3. ACTH signals the adrenal glands to produce and release cortisol.
4. Cortisol then feeds back to the hypothalamus and pituitary, suppressing further CRH and ACTH release — a classic negative feedback loop.

This feedback system is central to stress immune tolerance. When it works properly, the immune system gets a regulated cortisol signal that helps it distinguish between genuine threats and harmless tissue. When the HPA axis is chronically activated — by ongoing stress, trauma, inflammatory disease, or poor sleep — the feedback loop degrades. The system becomes either hyperactive (pumping out too much cortisol) or hyporeactive (burning out and producing too little).

Both extremes are problematic for autoimmune HPA function:

• Chronic HPA hyperactivity leads to the glucocorticoid resistance described above. Immune cells stop listening to cortisol's stop signals, allowing inflammatory processes to run unchecked.
• HPA hyporeactivity or blunting — sometimes seen in longer-standing autoimmune disease — leaves the immune system without adequate anti-inflammatory braking, potentially worsening autoimmune inflammation directly.

A 2025 review published in the context of cortisol immune dysregulation research confirmed that this bidirectional HPA dysfunction is a consistent feature across multiple autoimmune diseases, not an artifact of any single study population.

Research has also identified that CRH itself — not just cortisol — has direct pro-inflammatory effects in peripheral tissues. CRH receptors have been found on mast cells, T cells, and macrophages, meaning that the stress signal can activate inflammation even before cortisol is produced. This adds another layer to why the autoimmune HPA relationship is not simply about cortisol levels in isolation.

---

---

Are Cortisol Levels High or Low in Autoimmune Disease?

This is one of the most common questions people ask when they first encounter cortisol autoimmune research, and the honest answer is: it depends on the disease, the disease stage, and how cortisol is measured.

The research does not give a single, uniform answer. Here is what the evidence actually shows:

Evidence for Elevated Cortisol

A 2017 study found that women with autoimmune diseases had significantly higher hair cortisol concentrations and higher salivary cortisol compared to healthy controls. This finding was important because hair cortisol reflects cumulative exposure over weeks to months, not just a snapshot — meaning these women showed evidence of greater long-term HPA-axis activity, not just an acute stress response on a particular testing day.

A 2024 study published in research examining whether HPA-axis responses differ between autoimmune patients and healthy people found that women with systemic lupus erythematosus (SLE) had significantly higher one-day cortisol area-under-the-curve (AUC) values compared to healthy controls (p = 0.004). Women with systemic sclerosis also showed significantly higher cortisol AUC values (p = 0.001). These are statistically robust differences, and the AUC measurement captures total cortisol exposure across the day, providing stronger evidence than a single morning blood draw.

These findings align with the idea that active systemic autoimmune disease drives sustained HPA activation — possibly because the ongoing inflammatory burden acts as a continuous stressor on the axis.

Evidence for Altered or Blunted Cortisol

Other research, particularly in rheumatoid arthritis and longer-duration disease, has found evidence of blunted HPA responses — where the axis fails to mount an adequate cortisol response to acute stress. This may represent a burned-out or reset system after years of chronic activation, or it may reflect direct autoimmune damage to HPA components.

In patients receiving glucocorticoid therapy, a 2016 study found that both basal and stimulated ACTH and cortisol levels decreased significantly, demonstrating measurable HPA-axis suppression from treatment. This is a clinically important finding: long-term steroid use for autoimmune management can itself alter the HPA axis, making it harder to distinguish disease-related cortisol changes from medication effects.

The takeaway from this body of cortisol autoimmunity research is that you cannot assume a simple "high or low" answer. The cortisol profile in autoimmune disease is dynamic, disease-specific, and affected by treatment history.

---

Cortisol Research in Lupus, Hashimoto's, and Rheumatoid Arthritis

Several specific autoimmune diseases have accumulated the most robust research on cortisol and HPA-axis function. Here is what the evidence shows for the three most studied conditions.

Stress Lupus Research

Systemic lupus erythematosus (SLE) has one of the clearest documented relationships with cortisol dysregulation. Stress lupus research consistently shows that psychological stress precedes lupus flares in a significant proportion of patients, and the mechanism appears to involve HPA-axis activation triggering immune shifts.

The 2024 study mentioned above specifically reported elevated cortisol AUC in SLE patients versus healthy controls (p = 0.004), suggesting sustained HPA hyperactivity in active disease. Earlier work had also shown that women with lupus have altered diurnal cortisol rhythms — flatter curves across the day rather than the normal steep morning peak and evening trough — which is a pattern associated with immune dysregulation and elevated inflammation in other contexts.

Additionally, lupus itself damages multiple organ systems, including — in some cases — the adrenal glands. This creates the potential for both hyperactivity early in disease and relative adrenal insufficiency in later stages or after glucocorticoid exposure.

Cortisol Hashimoto's Research

Hashimoto's thyroiditis, the most common autoimmune condition in developed countries, has its own cortisol story. Cortisol Hashimoto's research from 2016 found a specific and quantifiable relationship: each 1 nanogram increase in cortisol was associated with a 19% increase in the adjusted odds of having Hashimoto's thyroiditis. That is a meaningful effect size for a single-unit hormone change.

The proposed mechanism involves cortisol's interaction with thyroid hormone metabolism and its effects on thyroid-specific immune regulation. The thyroid gland is unusually sensitive to stress-related hormonal changes, and the HPA-thyroid axis cross-talk is an active area of research. Elevated cortisol can suppress TSH, alter T4-to-T3 conversion, and shift the immune environment toward the Th1-dominant pattern associated with autoimmune thyroid disease.

There is also evidence that people with Hashimoto's show more anxious temperament profiles and higher rates of prior stressful life events compared to controls, though this type of retrospective research is difficult to interpret causally.

Stress RA Research

Rheumatoid arthritis (RA) has been studied extensively in the context of stress and HPA function. Stress RA research shows a mixed picture: some studies find elevated cortisol during active disease, while others document blunted cortisol awakening responses (CAR) — a well-validated marker of HPA function — in established RA.

One consistent finding is that the HPA axis in RA patients does not respond as robustly to acute stressors as it does in healthy controls, even when basal cortisol may appear normal or high. This relative HPA hyporesponsivity has been proposed as a factor that allows joint inflammation to persist, since the cortisol signal that would normally dampen synovial inflammation is inadequate.

Furthermore, RA patients show higher rates of depression and anxiety than the general population, and stress-related HPA dysregulation is thought to be a bidirectional link — stress worsens RA activity, and the chronic pain and disability of RA perpetuate stress-related HPA changes.

---

How Researchers Measure Cortisol in Autoimmune Studies

Understanding cortisol and autoimmune disease research requires understanding that not all cortisol measurements are the same. Different methods capture different aspects of HPA-axis function, and the choice of measurement significantly affects what a study can and cannot conclude.

Blood Cortisol

Serum or plasma cortisol is the most commonly used clinical measure. A standard morning blood draw captures peak cortisol output in most people. However, a single blood measurement is highly sensitive to acute stress, time of day, and other variables. It does not capture diurnal rhythm abnormalities or chronic exposure patterns.

In research settings, timed blood draws (multiple samples across a day) or ACTH stimulation tests (measuring cortisol response to synthetic ACTH) provide more useful data about HPA-axis function than a single morning value.

Salivary Cortisol

Salivary cortisol is increasingly used in autoimmune research because it is non-invasive, can be collected at multiple time points in natural settings, and measures free (biologically active) cortisol rather than total cortisol bound to carrier proteins. The cortisol awakening response — measuring the spike in cortisol in the first 30-45 minutes after waking — is one of the most studied salivary measures in psychoneuroimmunology research.

The 2017 study that found higher salivary cortisol in women with autoimmune disease used this method, allowing researchers to capture diurnal patterns that a single blood draw would miss.

Hair Cortisol

Hair cortisol analysis is a newer and increasingly valuable tool in cortisol immune dysregulation research. Because hair grows approximately 1 centimeter per month, a 3-centimeter hair sample captures roughly 3 months of cumulative cortisol exposure. This makes it uniquely useful for studying chronic, long-term HPA activity — the type most relevant to autoimmune risk.

The 2017 study found elevated hair cortisol in autoimmune disease patients, complementing the salivary findings and providing evidence that elevated cortisol exposure in these women was not a momentary phenomenon.

Urinary Cortisol

24-hour urinary free cortisol provides an integrated measure of daily cortisol production and is used in clinical evaluation of Cushing's syndrome, but is less commonly used in autoimmune research due to practical collection difficulties.

Each method has its place, and the most informative studies tend to combine multiple measures to build a fuller picture of HPA-axis function across time.

---

---

Chronic Stress, Cortisol Dysregulation, and Autoimmune Risk

Perhaps the most clinically significant question in this field is whether chronic stress — through its effects on cortisol and the HPA axis — actually increases the risk of developing autoimmune disease, or whether cortisol changes are simply a downstream consequence of having an inflammatory condition.

The 2025 review "Chronic Stress and Autoimmunity: The Role of HPA Axis and Cortisol Dysregulation" addressed this question directly. It summarized both clinical and population-level evidence and concluded that chronic stress can promote cortisol dysregulation, drive pro-inflammatory signaling, and meaningfully increase autoimmune disease risk. This is not just a theoretical framework — it is supported by epidemiological data, animal models, and mechanistic studies.

Key mechanisms linking chronic stress to autoimmune risk include:

1. Glucocorticoid resistance in immune cells As described earlier, prolonged cortisol elevation causes immune cells to downregulate glucocorticoid receptors. T regulatory cells (Tregs) — which are critical for preventing autoimmune attacks — are particularly sensitive to this desensitization. Reduced Treg function allows autoreactive T cells to escape suppression, which is a foundational step in autoimmune pathogenesis.

2. Shift from Th1 to Th2 and back again Cortisol classically shifts immune responses away from cell-mediated Th1 immunity toward humoral Th2 immunity. In a simplified early model, this was thought to be protective against autoimmune disease. However, more current research shows that chronic cortisol dysregulation does not produce a clean Th1/Th2 shift — it disrupts the Th17/Treg balance, which is more directly implicated in most modern autoimmune disease models.

3. Inflammatory cytokine upregulation When the HPA axis becomes dysregulated, the normal cortisol-mediated suppression of cytokines like IL-6, TNF-alpha, and IL-1β breaks down. These cytokines are central to autoimmune inflammation. A loss of adequate cortisol signaling allows these pro-inflammatory mediators to operate with less restraint.

4. Epigenetic changes Chronic stress exposure, particularly early in life, can produce lasting epigenetic changes to genes involved in HPA function and immune regulation. These changes may persist long after the original stressor has resolved, creating a biologically embedded vulnerability to stress-triggered autoimmune dysregulation in adulthood.

5. Microbiome disruption Chronic stress alters gut permeability and microbiome composition via both cortisol-dependent and cortisol-independent pathways. Gut dysbiosis is increasingly recognized as a contributor to immune dysregulation and autoimmune onset, creating another pathway through which stress affects autoimmune risk.

Population studies have consistently found that individuals reporting high levels of chronic psychological stress, trauma history (particularly adverse childhood experiences), and work-related burnout have higher rates of autoimmune diagnoses. This association persists after adjusting for confounders, though causality is inherently difficult to establish in observational research.

---

Does Glucocorticoid Therapy Change Long-Term HPA Function?

This is an important and often underappreciated dimension of cortisol autoimmune science. Millions of people with autoimmune diseases take synthetic glucocorticoids — prednisone, methylprednisolone, hydrocortisone — as part of their treatment. What does this do to the HPA axis?

The 2016 study in systemic autoimmune disease patients receiving glucocorticoid therapy found that both basal and stimulated ACTH and cortisol levels decreased significantly during treatment. This reflects therapy-induced HPA-axis suppression: when the body detects high levels of circulating glucocorticoids, it reduces its own production through the negative feedback loop described earlier.

The clinical consequences of this suppression include:

• Adrenal insufficiency risk if glucocorticoids are stopped too quickly. The adrenal glands, having been suppressed, may not immediately resume adequate cortisol production. This is why tapering protocols are essential.
• Loss of endogenous anti-inflammatory protection. The HPA axis normally produces cortisol in response to immune flares and physical stressors. In a suppressed axis, this protective response is blunted.
• Altered immune setpoints. Long-term glucocorticoid exposure changes the immune landscape in ways that go beyond what the drug is doing at any given moment — including effects on lymphocyte populations, cytokine production, and immune memory.

The interaction between exogenous glucocorticoids and the autoimmune HPA axis is bidirectional and complex. Treatment that is essential for managing acute disease can create vulnerabilities in long-term HPA resilience. This is an active area of research, particularly as clinicians look for strategies to minimize steroid burden while maintaining disease control.

A 2025 review examining corticosteroid-related immune effects confirmed that the immunological consequences of glucocorticoid therapy extend beyond simple immunosuppression, affecting innate and adaptive immune pathways in nuanced ways that are still being mapped out.

---

Is Cortisol Protective or Harmful in Autoimmune Inflammation?

This question sits at the philosophical heart of cortisol and autoimmune disease research, and the answer is genuinely "both, depending on context."

When Cortisol Is Protective

In acute settings, cortisol is clearly protective against excessive immune activation. It:

• Suppresses pro-inflammatory cytokine production
• Reduces vascular permeability and tissue edema
• Inhibits the migration of neutrophils and monocytes into inflamed tissue
• Promotes the resolution of acute inflammation

This is why glucocorticoids are among the most effective treatments available for acute autoimmune flares — they mimic and amplify the body's own anti-inflammatory cortisol response.

In autoimmune disease specifically, research has suggested that inadequate cortisol responses — situations where the HPA axis fails to mount sufficient cortisol output in response to immune activation — may allow inflammation to spiral in ways it would not in a healthy HPA axis. Some researchers have proposed that relative adrenal insufficiency in certain autoimmune conditions contributes to disease severity.

When Cortisol Is Harmful

Chronically elevated cortisol shifts from protective to damaging through several mechanisms already described: glucocorticoid resistance, epigenetic remodeling, microbiome disruption, and metabolic consequences. Beyond these immune effects, chronically high cortisol causes:

• Bone loss (a significant concern in long-term autoimmune management)
• Hyperglycemia and increased risk of metabolic syndrome
• Hippocampal atrophy and cognitive changes
• Cardiovascular risk elevation
• Further HPA axis dysregulation in a self-perpetuating cycle

The critical insight from contemporary cortisol immune dysregulation research is that the timing, pattern, and duration of cortisol elevation matter as much as absolute levels. A morning cortisol spike is physiologically appropriate. A flattened diurnal curve with sustained elevation across the day is not — and it is the latter pattern that appears most consistently in autoimmune disease contexts.

---

---

Frequently Asked Questions

Does cortisol cause autoimmune disease, or does it just reflect stress?

Current cortisol autoimmunity research suggests the relationship goes both ways. Chronic HPA dysregulation and cortisol abnormalities appear to contribute to autoimmune risk through the immune mechanisms described in this post — particularly glucocorticoid resistance and Treg dysfunction. But once autoimmune disease is established, the ongoing inflammatory burden also activates the HPA axis, producing cortisol changes that reflect disease activity. It is not a simple cause-and-effect relationship; it is a feedback loop.

Are cortisol levels always elevated in autoimmune disease?

No. The research shows disease-specific and stage-specific patterns. Active systemic diseases like SLE and systemic sclerosis show elevated cortisol AUC measures. Rheumatoid arthritis research often shows blunted cortisol responses to acute stress despite potentially normal basal levels. Hashimoto's thyroiditis shows a dose-dependent cortisol-risk relationship. Long-term glucocorticoid treatment suppresses both basal and stimulated cortisol. The picture is heterogeneous, which is why individual testing and interpretation require clinical context.

Can chronic stress worsen autoimmune symptoms?

Yes, and this is one of the more consistent findings in stress autoimmune research. Psychological stress, particularly when chronic, has been associated with autoimmune flares in lupus, RA, multiple sclerosis, and inflammatory bowel disease. The mechanisms include HPA-axis activation, sympathetic nervous system effects on immune function, behavioral changes (sleep disruption, altered diet, reduced medication adherence) and direct neuroimmunological pathways including the CRH-mast cell axis.

How do salivary, hair, and blood cortisol tests differ?

Each captures a different temporal window of cortisol exposure. Blood cortisol gives a snapshot of current (or morning peak) cortisol. Salivary cortisol at multiple time points captures the diurnal rhythm and awakening response. Hair cortisol captures cumulative exposure over months. For autoimmune research, combinations of these methods provide the most complete picture. Clinically, blood cortisol remains most commonly used, but salivary testing is gaining traction in functional medicine and research contexts.

Do glucocorticoid medications change long-term autoimmune risk?

This is an area of ongoing research. In the short to medium term, glucocorticoids clearly suppress autoimmune inflammation effectively. Long-term use suppresses the HPA axis, creates glucocorticoid resistance in some immune populations, and alters the immune landscape in complex ways. Whether this changes the underlying autoimmune risk — as opposed to managing active disease — is not fully established. What is clear is that long-term glucocorticoid use has significant side effects, and tapering strategies matter for HPA recovery.

Which autoimmune diseases have the strongest cortisol and HPA-axis findings?

Based on current evidence, SLE (elevated cortisol AUC with statistical significance in 2024 research), Hashimoto's thyroiditis (dose-dependent cortisol-risk association in 2016 research), systemic sclerosis (elevated cortisol AUC, p=0.001 in 2024), and rheumatoid arthritis (documented blunted CAR and HPA hyporesponsivity) have the most robust published findings. Multiple sclerosis, type 1 diabetes, and inflammatory bowel disease also have significant HPA-related research, though these were not the focus of this review.

Is there anything that can support healthy HPA function in autoimmune disease?

This is a clinical question that goes beyond the research scope of this post, and individual situations vary enormously. However, stress autoimmune research broadly supports the therapeutic value of interventions that reduce chronic stress load and support HPA resilience — including evidence-based psychological therapies (CBT, mindfulness), sleep optimization, regular physical activity calibrated to individual capacity, and addressing other inflammatory inputs. These should always be discussed with and guided by qualified healthcare providers, particularly in the context of an active autoimmune condition.

---

Key Takeaways

The field of cortisol and autoimmune disease research has moved well beyond simple hypotheses about stress causing immune problems. Here is what the current evidence most clearly supports:

1. The HPA axis is consistently dysregulated in autoimmune diseases, with patterns that vary by disease type, disease stage, and treatment history. The autoimmune HPA relationship is bidirectional and self-reinforcing.

1. Chronic stress promotes cortisol dysregulation that can contribute to autoimmune risk through glucocorticoid resistance, Treg dysfunction, pro-inflammatory cytokine release, and epigenetic changes — not just through temporary immune activation.

1. Cortisol levels in autoimmune disease are not uniformly high or low. Active systemic diseases like SLE and systemic sclerosis show elevated cortisol AUC (2024 data). Hashimoto's research shows a specific dose-dependent risk association. RA shows HPA hyporesponsivity patterns. Measurement method and timing matter enormously.

1. Hair and salivary cortisol measures capture chronic and rhythmic patterns that single blood draws miss — and these methods have consistently revealed HPA abnormalities in autoimmune populations that standard clinical testing might overlook.

1. Glucocorticoid therapy, while essential for acute autoimmune management, suppresses the HPA axis, which has clinical consequences for adrenal function and long-term immune regulation that require careful management.

1. Cortisol is not simply "bad" or "good" in autoimmune inflammation — acute, patterned cortisol responses are protective, while chronic, dysregulated cortisol exposure becomes harmful through the same immune pathways it normally regulates.

1. The most recent research (2024–2025) continues to strengthen the case for chronic stress and HPA-axis dysregulation as meaningful contributors to autoimmune disease risk and progression, not just as epiphenomena of having a chronic illness.

---

The information in this post is intended for educational purposes based on published scientific research. It does not constitute medical advice. Always consult qualified healthcare professionals regarding diagnosis, treatment, or changes to your healthcare regimen for any autoimmune condition.

---

References and Further Reading

1. "Chronic Stress and Autoimmunity: The Role of HPA Axis and Cortisol Dysregulation" (2025 review) — PMC/NCBI
2. "Does stress response axis activation differ between patients with autoimmune disease and healthy people?" (2024) — PubMed, PMID 38454759
3. Hair and salivary cortisol in women with autoimmune disease vs. healthy controls (2017)
4. Cortisol and Hashimoto's thyroiditis odds ratio analysis (2016)
5. HPA-axis suppression in systemic autoimmune disease patients on glucocorticoid therapy (2016)
6. Frontiers review on stress, immunity, and corticosteroid-related immune effects (2025)
7. News-Medical.net: The Link Between Cortisol, Inflammation, and Disease